Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

2022: Year Of The Great Rotation

Published 01/05/2022, 12:44 PM
Updated 05/14/2017, 06:45 AM

Welcome to 2022. More than ever, we believe it is time to get out with the old and in with the new.

At Crescat, we believe investors today face a twofold problem:

  1. The imperative to not get sucked into a financial asset bubble destined to implode.
  2. The need to outpace structurally rising inflation.

Starting from historically stretched valuations, inflation is the catalyst that can and should both crush price-to-earnings multiples and lead to rising interest rates. It can be especially destructive to overpriced large cap growth and mega-cap tech stocks.

As an overarching macro investment theme at Crescat today, we have been preparing for the Great Rotation. We believe this theme is a tectonic shift out of hyper-overvalued, long-duration financial assets and into a narrower undervalued segment of the market that is focused on the tangible assets at the core of the global economy. It is a collision of macro worldviews and investment flows with one much larger crowded pool of assets ready to swamp the other tiny one to only further ignite the inflationary catalyst, a feedback loop of monumental proportion.

2021 was a year where we saw glimpses under the surface of this transition beginning. But overall, the imbalances only grew more extreme. The economy is not on sound footing for a new economic expansion because there has been no purging of the valuation excesses from the last cycle.

We have honestly never been more excited about our positioning and the opportunity to deliver solid inflation beating returns on both the long and short side of our portfolios in the coming months and years.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

A Change Already Underway In 2022

Right from the starting gun of 2022, the US 10-year yield broke out to the upside from a 3-year resistance. Multiple macro forces are behind this rise in nominal rates. Among the most important ones, the flood of long-dated Treasury issuances is what truly concerns us. As we have explained in prior letters, this dynamic is part of a transition that the US government is undertaking by rolling maturing short-term Treasuries into long term debt instruments as it prepares to inflate out of an unsustainable debt problem.

Just in the last 3 months, we saw almost $600 billion of Treasury bonds and notes being issued. Meanwhile, as inflation continues to prove to be more persistent than it initially expected, the financier to the current fiscal imprudence aims to tighten the reins. The Fed has been responsible for about 35 to 40% of new Treasury issuances in the last months. Without them as the lender of last resort, we believe the Treasury market will be facing a major supply-demand mismatch.

For the first time in a very long-time we are seeing a significant increase in cost of capital unfolding across developed economies. The outstanding value of negative yielding bonds has drastically decreased worldwide, peaking in December 2020 at $18.3 trillion. It is now in free-fall, back to $10.7 trillion.

This is an important part of the macro regime change that we have been calling for. It is a hostile market environment for long-duration assets that currently trade at historical multiples, i.e., tech stocks. These companies have rejoiced from a disinflationary setup for decades and are ripe to be re-rated at significantly lower prices in our view.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Software companies, for instance, have already started to price in this market risk. As part of Russell 3000 (NYSE:IWV), the median performance for software and technology services is now down 27% from its 52-week moving average. Outside of the technology sector, non-profitable businesses like biotechnology companies are also suffering tremendously from this major rotation out of long-duration assets. In fact, the SPDR® S&P Biotech ETF (NYSE:XBI) is now down 36% since February 2021. The underperformance of software and biotechnology stocks explains why the over-hyped growth investments like the ARK Innovation ETF (NYSE:ARKK) have done so poorly in the last months. These are all strong signs that a reckoning moment for the stock and bond markets at large is upon us.

Still, there is a narrower value-oriented segment of the stock market that will thrive in this rotation. We believe unloved yet highly profitable energy and materials-oriented businesses with strong balance sheets, low fundamental multiples, and high intermediate-term growth rates will benefit from the inflationary environment that is already under development. That is precisely the reason why our hedge funds remain heavily exposed on the long side to natural resource industries. We think commodity-related stocks will continue to outperform relative to the current speculatively overvalued parts of the market.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.